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Purpose. The application of therapeutic proteins is often hampered by limited cell entrance and
lysosomal degradation, as intracellular targets are not reached. By encapsulation of proteins into
targeted liposomes, cellular uptake via endocytosis can be enhanced. To prevent subsequent lysosomal
degradation and promote endosomal escape, photochemical internalization (PCI) was studied here as a
tool to enhance endosomal escape. PCI makes use of photosensitising agents which localize in endocytic
vesicles, inducing endosomal release upon light exposure.
Materials and Methods. The cytotoxic protein saporin was encapsulated in different types of targeted
liposomes. Human ovarian carcinoma cells were incubated with the photosensitiser TPPS2a and
liposomes. To achieve photochemical internalization, the cells were illuminated for various time periods.
Cell viability was used as read-out. Illumination time and amount of encapsulated proteins were varied
to investigate the influence of these parameters.
Results. The cytotoxic effect of liposomally targeted saporin was enhanced by applying PCI, likely due
to enhanced endosomal escape. The cytotoxic effect was dependent on the amount of encapsulated
saporin and the illumination time.
Conclusion. PCI is a promising technique for promoting cytosolic delivery of liposomally targeted
saporin. PCI may also be applicable to other liposomally targeted therapeutic proteins with intracellular
targets.
KEY WORDS: cytosolic delivery; endosomal escape; liposomes; photochemical internalisation;
protein delivery.
INTRODUCTION
An increasing number of biomolecules, like proteins and
nucleic acids, are being developed for therapeutic use.
However, intracellular delivery of such macromolecules to
their target sites present in the cytosol or nucleus is often
inefficient. Their hydrophilic and charged nature together
with their high molecular weight, make cell membrane
passage difficult. Furthermore, these molecules often have
poor pharmacokinetic and biodistribution properties and are
highly susceptible to degradation by extra- and intracellular
enzymes. Therefore, delivery systems, like liposomes, are
required to improve the therapeutic efficacy of labile
macromolecular drugs. Liposomes can improve pharmacoki-
netics, provide protection from degradation, mediate target-
ing to the pathological site and facilitate uptake by the target
cells (1,2). However, although pharmacokinetics, tissue
distribution, and cellular uptake can be improved using
(targeted) liposomes, the liposomal drug usually ends up in
the endo- and lysosomes, where both the liposome particles
as well as the encapsulated macromolecules are subject to
degradation (3,4).
Therefore, endosomal escape of liposome-encapsulated
macromolecules is a vital issue in drug delivery research. In
the liposome field, various approaches are being investigated
to realize endosomal escape of liposomal contents. One
approach makes use of lipids with pH-dependent membrane-
destabilizing properties. Upon acidification, as occurring in
the endosomal/lysosomal compartment where the targeted
liposomes end up after internalization by target cells, these
lipids undergo a phase transition and when incorporated in
the liposomal membrane, they promote fusion with and/or
destabilization of the endosomal membrane. The most
commonly used lipid in this context is dioleoyl phosphatidyl
ethanolamine (DOPE) in combination with acidic lipids such
as cholesteryl hemisuccinate (CHEMS), oleic acid (OA),
N-palmitoyl homocysteine (PHC) and dipalmitoyl succinyl
glycerol (DSPG). This approach is adequately reviewed in
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reference (5). Lee et al. reported on the successful cytosolic
delivery of liposomal contents by co-encapsulation of the
pore forming protein listeriolysin O (LLO) in pH-sensitive
liposomes. This delivery system mimics the intracellular
invasion strategy of the pathogen Listeria monocytogenes
which uses LLO to escape from the endosomes (6–8). Co-
encapsulation of a fusogenic peptide derived from the influenza
virus hemagglutinin resulted in efficient cytosolic delivery of
liposomal diphtheria toxin A-chain as reported by Mastrobattista
et al. (9). Kakuda et al. demonstrated that the insertion of
cholesterol derivatized GALA-peptide into the liposomal bilayer
also stimulated release of liposomal contents into the cytosol (10).
Recently a new technique, referred to as photochemical
internalization (PCI) has been reported to be useful for the
promotion of endosomal escape of macromolecules or partic-
ulate systems (reviewed in (11)). The technique is based on
the specific localization of a photosensitiser in endosomal
membranes. Photosensitisers with an amphiphilic nature will,
when added to cells, localize in the plasma membranes and,
upon endocytosis, accumulate primarily in endosomal mem-
branes. Including a photosensitizer free incubation period in
the experimental PCI protocol will ascertain localization of
the photosensitizer predominantly in the endosomal mem-
branes. Upon illumination, highly reactive singlet oxygen
species are formed which damage the endosomal membranes
and make it permeable for endocytosed material. Upon
illumination release of lysosomal enzymes into the cytosol
was observed without extensive cell death (12).
The plant toxins gelonin and saporin, members of the
type I ribosome-inactivating protein family, lack specific
domains for cell entrance and if they are taken up via
endocytosis, they will be degraded within the endosomal/
lysosomal pathway. However, if they are delivered into the
cytoplasm, their potent inhibitory effect on the cellular
protein synthesis results in severe cytotoxicity (13). There-
fore, these macromolecules are useful for demonstrating the
occurrence of endosomal escape.
The recently introduced technique PCI was applied for
the cytosolic delivery of saporin via liposomes. Saporin was
encapsulated into different types of liposomes, designed to
deliver the toxin into EGF-receptor positive human ovarian
cancer cells. To stimulate cellular uptake, positively charged
and EGF-receptor targeted liposomes were employed. As
cytotoxic activity of liposomal saporin was only observed in
combination with PCI, it is demonstrated here for the first
time that the combination of the use of targeted liposomes




Egg-phosphatidylcholine (EPC) and 1,2-distearoyl-glyc-
ero-3-phosphoethanolamine-N-[poly(ethylene glycol)2000]
(PEG2000-DSPE) were obtained from Lipoid GmbH (Lud-
wigshafen, Germany). Maleimide-PEG2000-DSPE (Mal-
PEG-DSPE) was obtained from Shearwater Polymers
(Huntsville, AL, USA). 1,2-dioleoyl-3-trimethylammonium-
propane chloride salt (DOTAP) was purchased from Avanti
Polar Lipids (Alabaster, AL, USA). Cholesterol (CHOL),
S-acetylthioglycolic acid N-hydroxysuccinimide ester (SATA),
XTT sodium salt and saporin were purchased from Sigma-
Aldrich Co. (St. Louis, MO, USA). Titriplex III (EDTA) was
obtained from Merck (Darmstadt, Germany). Hepes was
purchased from Acros (Geel, Belgium). Hydroxylamine
hydrochloride was from ICN Biomedicals (Aurora, OH,
USA). 125I was purchased from Amersham Biosciences
(Diegem, Belgium).
1,1¶-dioctadecyl-3,3,3¶,3¶-tetramethylindocarbocyanine,
4-chlorobenzenesulfonate sulfonate salt (DiD) was
obtained from Molecular Probes Europe BV (Leiden,
The Netherlands). Murine monoclonal antibody mAb425 of
isotype IgG2b, directed against the human epidermal growth
factor receptor (EGFR) was kindly donated by Merck KGaA
(Darmstadt, Germany). Irrelevant isotype matched murine
monoclonal antibody directed against the influenza virus HA
(clone 12CA5) was kindly donated by Dr. E. Boot (Immunol-
ogy Division, Department of Infectious Diseases and Immu-
nology, Utrecht University, Utrecht, The Netherlands).
The photosensitiser LumiTransi (tetraphenylporphine
disulfonate, TPPS2a) was a generous gift from PCI Biotech
(Oslo, Norway).
Cell Culture
The human ovarian carcinoma cell line NIH:OVCAR-3
was obtained from the ATCC (Manassas, USA). The cells
were cultured in Dulbecco_s modified Eagle_s medium
containing 3.7 g/l sodium bicarbonate, 4.5 g/l L-glucose and
supplemented with L-glutamine (2 mM), 10% (v/v) fetal calf
serum (FCS), penicillin (100 IU/ml), streptomycin (100 mg/
ml) and amphotericin B (0.25 mg/ml) at 37-C with 5% CO2 in
humidified air. All cell-culture related material was obtained
from Gibco (Grand Island, NY, USA).
Liposome Preparation and Characterization
The solvent evaporation/hydration method was used to
prepare liposomes. Briefly, EPC, CHOL, PEG2000-DSPE and
maleimide-PEG2000-DSPE (molar ratio1.85:1.00:0.09:0.06) or
EPC, CHOL and DOTAP (molar ratio 4:1:1) were dissolved
in chloroform/methanol (2:1 v/v). For FACS analysis, 0.1
mol% DiD was added as fluorescent marker. After evapora-
tion of the solvent, the lipid film was hydrated with a solution
of 0.5 mg/ml or 0.1 mg/ml saporin in Hepes buffered saline
(HBS; 10 mM Hepes, 137 mM NaCl, pH 7.4). The liposomes
were sized to 150 nm by extrusion using a Lipex high
pressure extruder (Northern Lipids, Vancouver, Canada).
Non-encapsulated saporin was removed by size exclusion
chromatography using Separose CL-4B (Amersham Pharma-
cia Biotech, Uppsala, Sweden).
The monoclonal antibody mAb425 and the irrelevant
isotype antibody were modified with SATA to introduce
sulfhydryl groups randomly as described previously (14). In
short, an 8-fold molar excess of SATA dissolved in DMF was
added to the antibody solution (1/10 of volume) and
incubated for 45 min at room temperature. The non-coupled
SATA was removed using Vivaspin columns (MWCO 50,000
Da, Vivascience, Hannover, Germany). The sample was
centrifuged three times for 15 min at 5,500 rpm at 4-C and
washed with HBS pH 7.4.
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Before coupling of the antibody to the maleimide-deriva-
tized PEG-DSPE present on the liposome surface, the SATA-
group was activated using a hydroxylamine solution (0.5 M
Hepes, 0.5 M hydroxylamine HCl and 0.25 mM EDTA; pH 7.0)
for 1 h at room temperature. Coupling of the antibody to the
maleimide-PEG-DSPE present on the liposomal surface oc-
curred overnight at 4-C. Non-coupled antibody was removed by
size exclusion chromatography using Separose CL-4B.
The liposomes were characterized with respect to size
using dynamic light scattering, phospholipid content according
to Rouser (15) and amount of saporin encapsulated using 125I
determination.
Labeling of Saporin with 125I
Saporin was labelled with 125I using Iodobeads (Pierce,
Rockford, IL, USA). 5 MBq of a 125I-solution in 0.01 M
NaOH (370 MBq/100 ml) was diluted in 200 ml HBS pH 7.0
and incubated with two Iodobeads for 5 min at room
temperature. Subsequently, 1 ml of a saporin solution (1
mg/ml in water) was added and incubated for an additional
20 min at room temperature. Next, saporin and unbound 125I
were separated on a PD-10 column (Amersham Pharmacia
Biotech) using HBS pH 7.0 as an eluent. Specific activity was
determined by measuring activity on a Wallac 1480 BWizard 3^
sodium iodide counter and by detecting the UV absorbance at
280 nm using a Shimadzu UV-1601 spectrophotometer. The
specific activity was 1.6 MBq/mg protein.
Binding Studies
OVCAR-3 cells were detached from the culture flask by
trypsin/EDTA solution (0.05% (w/v) trypsin and 0.02% (w/v)
EDTA in PBS). Cells, (100,000) were incubated for 1 h with
fluorescently labelled liposomes at 4-C. Cells were washed
twice by centrifugation (300 g, 5 min, 4-C). Flow cytometry
analysis was performed using a FACScalibur (Beckton&
Dickinson, Mountain View, CA, USA) and data were
analysed using WinMDI 2.8 software, which was kindly
provided by Joseph Trutter.
Cellular Uptake of Liposomal Saporin
OVCAR-3 cells were seeded (105 cells/well) in 6-well
plates and cultured overnight prior to the experiment. The cells
were incubated for 18 h with saporin-liposomes (50 nmol
liposomal lipid). After three washing steps using PBS, the cells
were subsequently chased for 4 h with liposome free medium.
After washing, the cells were lysed with a 1% Triton X-100
solution (w/v in water) and frozen to j20-C. The thawed cell
lysate was used for analysis on the Wallac sodium iodide counter.
Efficacy Studies
OVCAR-3 cells (5103 cells/well) were seeded into 96-
well plates and cultured overnight prior to the experiment.
Culture medium was removed and fresh culture medium was
added containing either liposomes, photosensitiser or both.
The photosensitiser was always added at a final concentration
of 0.5 mg/ml, while the liposome concentration varied. After
18 h, liposomes and/or photosensitiser were removed and the
cells were incubated for 4 h with fresh culture medium before
75 s of illumination with the LumiSource (Osram 18W/67 with
light intensity 7 mW/cm2, PCI Biotech, Oslo, Norway). Cells
were incubated for another 48 h before the cell viability was
measured using the XTT assay as previously described (16).
Effect of Illumination Time
OVCAR-3 cells were incubated with 0.1 mM saporin-
liposomes and 0.5 mg/ml photosensitiser for 18 h and
subsequently for 4 h with complete culture medium. The
cells were illuminated for 45, 75 or 120 s. Cell viability was
assessed with the XTT assay 48 h after illumination.
Contribution of PDT to Cell Death
OVCAR-3 cells were incubated with 0.1 mM saporin-
liposomes and 0.5 mg/ml photosensitiser for 18 h and
subsequently for 4 h with complete culture medium. The
cells were illuminated for 45, 75 or 120 s. Cell viability was
assessed with the XTT assay 48 h after illumination. The
contribution of photodynamic therapy (PDT) effects to cell
death was calculated with the following formulas:
Total Cell Viability TCVð Þ
¼ Absorbance treated with liposomes; photosensitizer and lightð Þ
Absorbance non treatedð Þ
 
 100%
Cell Viability after PDT CVPDTð Þ
¼ Absorbance treated with photosensitizer and lightð Þ
Absorbance non treatedð Þ
 
 100%
Cell death PDT ¼ 100  CVPDT
Cell death PCI ¼ 100 Cell death PDT  TCV
Total cell death ¼ Cell death PDT þ Cell death PCI
¼ 100  TCV
Contribution of PDT to cell death




Contribution of PCI to cell death
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RESULTS AND DISCUSSION
Liposome Characteristics
The following liposome types were used to deliver
saporin into human ovarian carcinoma cells (OVCAR-3):
1. Cationic liposomes (DOTAP-L) were prepared by incorpo-
ration of the positively charged lipid DOTAP (17 mol% of total
lipid) into EPC/CHOL liposomes. The cationic nature of these
liposomes mediates a strong affinity for negatively charged
cell membranes (17). 2. Epidermal growth factor receptor
(EGFR) targeted PEG-liposomes (EGFR-L) were prepared
to target to the EGFR by coupling an anti-EGFR antibody to
the distal end of the PEG-chains. The EGFR is overexpressed
in several tumor cell lines and is an internalising receptor,
which makes it an attractive target for drug delivery (18). As
already shown by former studies in our laboratory, EGFR-L
can be used to specifically target OVCAR-3 cells (9). 3. PEG-
liposomes (PEG-L) without an antibody attached were used as
a control. Due to the PEG-layer surrounding these liposomes,
the cellular association and uptake by OVCAR-3 cells is low
as shown previously (9,19).
All liposome types used had a particles size between 140
and 160 nm and a polydispersity index <0.2, which indicates a
narrow size distribution. As quantified by 125I-saporin
determination, the encapsulated amount of saporin varied
between 0.3 and 0.9 mg/mmol lipid which correspond to an
encapsulation efficiency varying between 3.0 and 5.4%. The
fluorescent bilayer marker DiD was incorporated (0.1 mol%)
in case of experiments designed to monitor the cellular
binding of the liposomes.
Cellular Binding and Uptake of Saporin-Liposomes
The binding of the different liposome types to OVCAR-3
cells was investigated by flow cytometry using the fluorescent
bilayer marker DiD (Fig. 1a). The highest level of cellular
association was observed in case of the positively charged
DOTAP-L. Electrostatic interaction between the positively
charged DOTAP-L and negatively charged cell membranes
results in a strong binding. The use of targeted EGFR-L resulted
in a 20–60 fold increased fluorescence signal compared to non-
targeted PEG-L. This indicates that the EGFR-targeted li-
posomes do interact with the EGF-receptor expressed on the
OVCAR-3 cells and that targeting the EGF-receptor may be
useful for increasing the delivery of liposomal proteins. The
coupling of an irrelevant isotype match antibody to liposomes
results in a degree of cell binding of the liposomes which is
comparable to that of non-targeted PEG-liposomes. Further-
Fig. 1. Cellular binding and uptake of different liposome types
containing saporin. a Binding of different types of saporin-liposomes
to OVCAR-3 cells. Fluorescently labelled liposomes were incubated
for 1 h at 4-C with OVCAR-3 cells, washed and analysed by flow
cytometry. Data represents mean T SD (n=3). Error bars are within
plot symbol when not visible. Statistical analysis was performed using
a F-test. All curves are significantly different (P<0.0001). b Cellular
125I-saporin after 18 h incubation with liposomal 125I-saporin
followed by 4 h chase period with liposome free medium. Data
represent mean T SD (n=3). Statistical analysis was performed using
a one-way ANOVA (P<0.0001) followed by Newman-Keuls post-hoc
multiple comparison test (*P<0.05 and **P<0.001).
Fig. 2. Effect of PCI on cytotoxicity after exposure to liposomal
saporin a. Comparison of liposomal saporin with free saporin in
combination with PCI b. OVCAR-3 cells were incubated for 18
h with liposomes and photosensitiser, subsequently washed away and
incubation was continued for 4 h before the onset of 75 s of
illumination. Forty-eight hours after illumination, the cell viability
was assessed with the XTT assay. Data represent mean T SD (n=4).
Error bars are within plot symbols when not visible. Statistical
analysis was performed on Fig. 2a using an F-test. Curves are
significantly different (P<0.0001).
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more, competition by adding excess of free antibody could
partially reduce cell binding of the EGFR-L (results not shown).
Additionally, we measured the amount of cellular
saporin after incubation at 37-C using 125I-labeled saporin.
OVCAR-3 cells were incubated with DOTAP-L, EGFR-L or
PEG-L, all containing 125I-labeled saporin and the results
shown in Fig. 1b correspond to the cell-binding data in
Fig. 1a. The extent of liposome-mediated delivery of saporin
to the cells decreased in the following order: DOTAP-L >
EGFR-L > PEG-L. It is known that (targeted) liposomes can
be taken up by endocytosis, which in this case most probably
results in the degradation of the liposomal saporin in the
lysosomes (20). To Frescue_ saporin from degradation, we
included PCI in the treatment to achieve endosomal release
of the liposomal saporin.
Efficacy Studies
Recent studies have shown that the PCI technique is
capable to induce selective release of material from the
endosomes into the cytoplasm. Selbo et al. demonstrated that
the use of PCI enhanced the potency of the plant toxin
gelonin in inhibiting cellular protein synthesis by a factor of
300 (21). In addition, the low-molecular weight drug bleo-
mycin (22), antigenic peptides (23), immunotoxins (24,25),
peptide nucleic acids (26) and even colloidal carriers for gene
delivery (27–29) have been successfully delivered into the
cytosol via PCI. These agents generally are not able to reach
their intracellular target site efficiently, due to lack of
capability to pass cellular membranes and/or the occurrence
of degradation within endocytic vesicles. The endosomal
release of liposomal drugs enabled by PCI has not been
demonstrated yet. As liposomes have a prominent place in
the arsenal of advanced drug delivery systems developed
over the years, it is important to evaluate whether PCI can be
employed to further improve the efficacy of liposomal drug
formulations.
To investigate whether the PCI technique is able to
enhance the cytosolic delivery of liposomal proteins in vitro,
OVCAR-3 cells were incubated with different types of
saporin-liposomes and/or the photosensitiser TPPS2a and
subsequently illuminated to activate the photosensitiser.
Since the ribosome-inactivating protein saporin will only
have cytotoxic properties when delivered in its active form
into the cytosol, cell viability was chosen as read-out (13).
Fig. 2a shows the cell viability of OVCAR-3 cells after
incubation with the different types of liposomes and photo-
sensitiser, followed by illumination. Both DOTAP-L as well
as EGFR-L strongly decreased cell viability compared to
PEG-L, with DOTAP-L being superior over EGFR-L. Even
at the lowest concentration added (0.510j3 mM liposomes)
only 30% of the cells survived the treatment with saporin-
containing DOTAP-L in combination with PCI, compared to
75% survival when EGFR-L are used at this concentration.
Saporin in PEG-L was cytotoxic only at concentrations
higher than 10 mM, which is at a level of four orders of
magnitude higher than for EGFR-L and five orders of
magnitude higher than for DOTAP-L. When the cytotoxic
effect of saporin-liposomes in combination with PCI is
compared with that of free saporin combined with PCI
(Fig. 2b), it is obvious that both DOTAP-L and EGFR-L are
by far more cytotoxic due to the enhanced cytosolic delivery
of saporin. Combination of PCI with free saporin was
comparable to that of saporin-containing PEG-L combined
Fig. 3. Cytotoxicity after different control treatments. a OVCAR-3
cells were incubated with saporin-containing (empty circle, filled
diamond, filled square) or empty (asterisk) DOTAP-L in the
presence (filled diamond, asterisk, filled square) or absence (empty
circle) of photosensitiser for 18 h, subsequently washed away and
incubation was continued for 4 h before 75 s illumination (asterisk,
filled square). Cell viability was assessed 48 h after illumination with
the XTT assay. b OVCAR-3 cells were incubated with saporin-
containing (filled square, filled triangle) or empty (filled upside down
triangle) immunoliposomes and photosensitizer for 18 h, subsequent-
ly washed and incubation was continued for 4 h before 75 s
illumination. Cell viability was assessed 48 h after illumination with
the XTT assay. The liposomes contained either an antibody targeting
the EGFR (filled square, filled upside down triangle) or an aspecific
antibody (filled triangle). Data represents mean T SD (n=4). Error
bars are within plot symbols when not visible.
Fig. 4. Effect of illumination time on cytotoxicity after treatment
with saporin-liposomes with PCI. OVCAR-3 cells were incubated
with 0.1 mM saporin-containing liposomes and 0.5 mg/ml photo-
sensitiser for 18 h, subsequently washed away and incubation was
continued for 4 h before the onset of illumination (45, 75 or 120 s).
Forty-eight hours after illumination, the cell viability was assessed
with the XTT assay. Data represents mean T SD (n=4). Statistical
analysis was performed using an F-test. Data is significantly different
(P<0.05).
2044 Fretz et al.
with PCI, indicating limited cytosolic delivery of saporin
yielding sub-threshold levels for cytotoxicity.
To demonstrate that the use of PCI is essential for
cytosolic delivery of saporin, different control experiments
were carried out. Fig. 3a demonstrates that only the
combination of saporin-liposomes (DOTAP-L) with both
photosensitiser and illumination (PCI) has cytotoxic proper-
ties. Empty DOTAP-L, i.e. devoid of saporin, were examined
and did not show any cytotoxicity in combination with PCI.
In addition, when saporin-containing DOTAP-L were used in
combination with only photosensitiser or only illumination or
neither of those, no decrease in cell viability was seen (data
not shown in case of saporin-containing liposomes in
combination with illumination, but without photosensitiser).
Analogous control experiments using of saporin-containing
EGFR-L showed similar results (data not shown). Fig. 3b
shows that saporin-liposomes with an irrelevant isotype
control antibody in combination with PCI did not decrease
the cell viability. This result demonstrates that the active
targeting of the liposomes using an anti-EGF-receptor
antibody is an essential requirement for these liposomes to
deliver saporin to the cytosol in combination with PCI. In
addition, empty EGFR-L in combination with PCI did not
cause any cytotoxicity indicating that the cytotoxicity of
saporin containing EGFR-L with PCI is not caused by an
EGF-receptor mediated cell death cascade.
Effect of Illumination Time
As illumination time may play a critical role, its effect on
the cytotoxic properties of saporin-liposomes in combination
with PCI was assessed. The effect of the illumination time on
cytotoxicity is shown in Fig. 4. A general trend can be
observed: the longer the illumination time, the stronger the
cytotoxic effect. This observation corresponds to observa-
tions done by others using PCI in combination with the plant
toxin gelonin (21,23). Routinely, we used 75 s as illumination
time in our experiments.
Contribution of PDT to Cytotoxicity
Photodynamic therapy (PDT) is a treatment that uses
photosensitising agents to kill tumor cells. Like in PCI,
reactive oxygen species are generated upon illumination of
the photosensitiser which damage cellular organelles like
mitochondria with cell death as an end result. Besides
damage to tumor cells, tumor associated vasculature can be
damaged. Furthermore, an immune response against tumor
cells can be induced leading to indirect tumor cell death
(30,31). To address the question to which extent cell death is
caused by the photosensitiser and illumination alone (i.e., a
PDT effect) and to which extent by the release of saporin
from the endosomes induced by the photosensitiser and
illumination (i.e., PCI), the relative contribution of a PDT
effect on the observed cytotoxicity was studied (Fig. 5). The
graphs show that the PDT effect is approximately 20% for
the shorter illumination times (45 or 75 s). On prolonged
illumination (120 sec) the PDT contribution to cell death is
increased to almost 50%. The total cell viability decreases
upon longer incubation (Fig. 4), which is mainly caused by
Fig. 5. Relative contribution of PDT and PCI to cytotoxicity.
OVCAR-3 cells were incubated with 0.1 mM saporin-containing
liposomes and 0.5 mg/ml photosensitiser for 18 h, subsequently
washed away and incubation was continued for 4 h before the onset
of illumination (45, 75 or 120 s). Forty-eight hours after illumination,
the cell viability was assessed with the XTT assay. PDT effect was
calculated as percentage cytotoxicity caused by photosensitizer and
illumination treatment alone. The cytotoxicity caused by PCI was
calculated by subtraction the PDT attribution from the total
cytotoxicity. Data represents mean T SD (n=4).
Fig. 6. Effect of encapsulated amount of saporin. OVCAR-3 cells
were incubated with DOTAP-L, which were prepared with a
hydration medium containing 0.1 or 0.5 mg/ml saporin in the
presence of photosensitiser for 18 h, washed away and incubation
continued for 4 h before the onset of the 75 s illumination. Cell
viability was assessed 48 h after illumination. Data represent mean T
SD (n=4). Error bars are within plot symbols when not visible.
Statistical analysis was performed using an F-test. Curved are
significantly different (P<0.01).
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the more pronounced PDT effect at longer illumination
times. Thus, efficient PCI is already achieved at the shorter
illumination times, without considerable PDT effect. Upon
prolonged illumination, PDT effects become more promi-
nent. Obviously, the occurrence of an additional PDT effect
in cancer treatment is beneficial as it will strengthen the PCI-
mediated anti-tumor effect.
Effect of Amount of Encapsulated Saporin
To investigate whether the amount of encapsulated
protein in the liposomes influences the PCI-promoted
cytoxicity, liposomes were prepared containing different
amounts of saporin. The results presented in Fig. 6 indeed
show that liposomes prepared by hydrating the lipid film
either in 0.1 or 0.5 mg/ml saporin, do differ substantially in
cytotoxic effect when combined with PCI up to a liposomal
lipid concentration of 0.5 mM. Above this concentration
similar cytotoxicity was observed.
The estimated EC50 values are 0.11 and 0.005 mM for
the low and high saporin-containing liposomes, respectively.
These results indicate that both the amount of encapsulated
toxin and liposomal lipid dose are important determinants of
PCI-promoted cytotoxicity.
In conclusion, this study demonstrates that PCI is a
useful tool to enhance the cytosolic delivery of liposomally
encapsulated proteins. By encapsulating saporin in positively
charged liposomes (DOTAP-L) or EGFR-targeted PEG-
liposomes (EGFR-L), the cytosolic delivery of saporin to
OVCAR-3 cells and resulting cytotoxicity was strongly
enhanced. The use of targeted liposomes (targeting mediated
by cationic charge or targeting ligand) appears essential, as
the cytotoxicity of saporin in non-targeted PEG-L was not
enhanced when compared to free saporin in combination
with PCI. Increasing the illumination time decreases the cell
viability, which is probably caused by an additional cytotoxic
PDT effect. We conclude that PCI is a promising technique
for promoting cytosolic delivery of liposomally targeted
proteins. In addition to proteins, also other macromolecules
like nucleic acids are expected to benefit from this liposomal
intracellular targeting approach. Fortunately, although this
paper is based on in vitro experimentation, the translation to
the in vivo situation is considerable favoured by the recent
developments in fibre optics and laser technology which have
made it possible to illuminate many sites in the human body.
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